CTLA4 and melanoma: In more recent independent studies, we have again observed predictive capacities of NY-ESO-1- and Melan-A-reactivities also for the outcome of melanoma patients under ICI with anti-PD-1 ± CTLA-4 antibodies (Zelba et al., personal communication) raising the question of potential advantages of T cells recognizing shared tumor antigens as one of several modules in future treatment strategies.